Therefore, on the basis of tumor expression rate, IGFBP-3 holds some promise as vaccine target because it suggests that around 43% of CRC patients could benefit from an IBF2BP3-based vaccine. This evidence concerns the gene IGFBP3 and colorectal carcinoma.